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Summary  
Standard integration-proficient lentiviral vectors (IPLVs) are effective at much lower doses 
than other vector systems and have shown promise in several gene therapy approaches. 
Their main drawback is the potential risk of insertional mutagenesis. Novel biosafety-
enhanced integration-deficient lentiviral vectors (IDLVs) offer a significant improvement 
and comparable transduction efficacy to their integrating counterparts in some central 
nervous system applications. We describe here methods for (1) production of IDLVs (and 
IPLVs), (2) IDLV/IPLV delivery into the striatum of a rat model of Parkinson's disease, and 
(3) post-mortem brain processing. 
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1. Introduction 
Gene therapy approaches have offered promise for many disorders, and lentiviral vectors 
(LVs) are one of the most attractive viral vector-based systems. LVs have many positive 
features derived from the biology of the corresponding natural viruses and their extensive 
vector development (1-3). In particular, LVs can transduce a variety of cell types of the 
central nervous system (CNS), including dividing as well as non-dividing cells, with stable 
long-term expression of the transgene (4, 5). However, a potential obstacle for the routine 
clinical use of current integration-proficient LVs (IPLVs) is the risk of insertional 
mutagenesis caused by integration of the viral provirus into the host cell genome (6). This 
risk could be addressed by using integration-deficient LVs (IDLVs), without a reduction in 
vector transduction efficiency if the target cell population does not divide significantly (7-9). 
It may also be possible to use replicating IDLVs for stable expression from viral episomes in 
dividing cells (10). 
IDLVs are commonly produced by targeted changes of individual amino acids within the 
catalytic active site of integrase (class I mutations), most frequently encoding a D64V 
change, which inhibit viral integration but leave other viral processes unaffected (11, 12). 
This strategy has mediated nearly complete (99%) inhibition of viral integration without 
significantly affecting proviral synthesis or infectious titres (9, 11-13). The failure to integrate 
into the host genome leads to increased levels of episomal viral DNA (8, 9, 14). These viral 
episomes are mostly converted into circles that lack replication signals, and are stable in 
quiescent cells but progressively diluted in proliferating cells (9). Hence, IDLVs are ideally 
suited for applications in the post-mitotic central nervous system (CNS) environment (9, 15, 
16). 
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Very recently, we have assessed bio-safety and transduction efficiency of IDLVs in an 
animal model of Parkinson’s disease, the 6-hydroxydopamine (6-OHDA)-lesioned rat, with 
IPLVs used as a reference (17). Examination of reporter gene (enhanced green fluorescent 
protein, eGFP) and therapeutic transgene (Glial cell-derived neurotrophic factor, GDNF) 
expression has shown efficient, long-lived and transcriptionally targeted expression from 
IDLVs in the striatum of injected rats. We have confirmed the lack of significant integration 
of IDLVs in injected rat brains by linear amplification-mediated PCR analysis followed by 
deep sequencing and insertion site analysis (17). 
We regard these results as very encouraging for future IDLV-mediated gene therapy 
approaches. In the current chapter, we provide a detailed description of protocols to 
produce IDLVs (and IPLVs). We also present methods for delivering LVs into the striatum 
of 6-OHDA-treated rats and for post-mortem brain processing. We hope that the 
comprehensive descriptions in this chapter will promote a broader application and facilitate 
the study of IDLVs in the CNS. 
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2. Materials:  
2.1. Lentiviral vector production 
1. HEK293T cells 
2. Culture medium: DMEM (Dulbecco’s modified Eagle’s medium) high glucose 
supplemented with 10% FBS (foetal bovine serum), 100 units/ml penicillin, 100 μg/ml 
streptomycin, stored at 4oC 
3. 15 cm tissue culture plates 
4. Tissue culture-grade water, stored at room temperature (RT) 
5. 1x endotoxin-free TE (Tris/EDTA) buffer, filter-sterilised through a 0.22 μm filter, 
stored at RT 
6. 2.5 M CaCl2: dissolved in water, filter-sterilised through a 0.22 μm filter, aliquoted, 
and stored at -20 or -80oC  
7. 2x HBS: 100 mM HEPES, 281 mM NaCl, 1.5 mM Na2HPO4, dissolved in water, 
adjusted to pH 7.12 (pH is crucial), filtered through a 0.22 μm filter, aliquoted, and 
stored at -20 or -80oC. Use freshly-thawed reagent only 
8. 1 M MgCl2: dissolved in water, filter-sterilised through 0.22 μm filter and stored at 
4oC 
9. DNAse I: stored at -20o C 
10. Polyallomer ultracentrifuge tubes 
11. Ultracentrifuge compatible with SV32-Ti rotor (Beckman Coulter, UK) 
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2.2. Stereotactic injection of LVs  
1. Sprague-Dawley rats (250-300 g), maintained in a standard 12-hour light/dark cycle 
with free access to food and water. Experiments are performed in accordance with 
the UK Animals (Scientific Procedures) Act, 1986 
2. Paxinos and Watson Rat Brain Atlas (18) 
3. Stereotactic frame (World Precision Instruments, UK) 
4. UltraMicroPump III (World Precision Instruments, UK) 
5. Ideal Micro drill (Harvard Apparatus, UK) 
6. Shaver 
7. Surgical tools (i.e. scalpels, scissors, tweezers, absorbable Vetsuture, Halsey needle 
holder) 
8. 25 µl injection syringe with compatible stainless steel 33G needle (Hamilton, UK)  
9. 5 ml syringes  
10. 26G needles  
11. 5% Emla cream (AstraZeneca, UK) 
12. Aqupharm solution (0.18% sodium chloride + 4% glucose) 
13. Isoflurane  
14. 100% Oxygen  
15. 70% ethanol 
16. ddH2O 
17. Heat pads 
18. Paper towels 
19. Clean cages with bedding, food, and water 
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20. LVs, kept on ice during procedure 
 
2.3. 6-OHDA lesioning  
1. All materials listed in Section 2.2, except #20  
2. 6-OHDA (6-Hydroxydopamine): dissolved in 0.9% sterile saline and 0.02% ascorbic 
acid (2.5 µg/µl). Store on ice, protect from light and use within a day 
3. Pargyline (5 mg/ml) and desipramine (25 mg/ml): dissolved in sterile water and 
stored at RT 
 
2.4. Post-mortem brain processing and immunohistochemistry staining 
1. CO2 chamber  
2. 1x PBS (phosphate buffered saline): 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4, dissolved in 1L water, adjusted to pH 7.4, and stored at RT 
3. 4% PFA (paraformaldehyde): dissolved in 1x PBS, adjusted to pH 7.4 and preferably 
used within a day (or stored at -20oC) 
4. Vibrating microtome (Campden Instruments, UK)  
5. Paint brush 
6. Blocking buffer: 1% BSA (bovine serum albumin) and 0.02% sodium azide, dissolved 
in 1x PBS-T (0.25% Triton X-100 in 1xPBS), and stored at 4oC 
7. 1 M Tris buffer: Trizma base dissolved in water, adjusted to pH 7.8 with 1M HCl, and 
stored at RT 
8. Sodium azide: 0.1% stock dissolved in water and stored at RT 
9. Mowiol solution:  
 Stir 4.8 ml glycerol and 2.4 g Mowiol in 6 ml water for 2 h, RT  
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 Add 12 ml of 0.2 M Tris buffer pH 8.5, 0.02% sodium azide 
 Incubate solution in 50-60oC water bath for 10 min, stirring frequently 
 Centrifuge at 5000 g for 15 min 
 Collect supernatant, aliquot and store at -20oC (see Note 1)  
10. PPD (p-Phenylenediamine) solution: 0.1% PPD dissolved in water, protected from 
light and stored at -20oC 
11. Mounting solution: mix 1 part of PPD solution with 9 parts of Mowiol solution; 
maintain at RT, protect from light and use within a day 
12. Antibodies (as required) 
13. DAPI (4,6-Diamidino-2-phenylindole): dissolved in water, protected from light and 
stored at -20oC 
14. SuperFrost slides and coverslips 
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3. Methods 
All in vitro work in section 3.1 is carried out under sterile cell culture conditions. 
 
3.1. Production of LVs by transient calcium phosphate transfection (5, 9, 19) 
1. Seed HEK293T cells in 15 cm plates (see Note 2 for cell density) and culture until the 
cells are around 60% confluent (~2x107/plate/25 ml medium) 
2. Two hours (minimum 30 min) prior to transfection of LV plasmids, replace the culture 
medium with 20 ml fresh medium per plate  
3. Prepare mixture of plasmid DNA in 15 or 50 ml Falcon tube. The amount below is for 
each 15 cm culture plate, scale up/down as required (see Note 3): 
 To produce 2nd generation LVs, use a three-plasmid system at molar ratio 1:1:2 of 
packaging:env:transfer plasmids: 
o Packaging plasmid (pCMVR8.74 for IPLVs or pCMVR8.74intD64V for 
IDLVs): 16.25 µg 
o Envelope plasmid (pMD2.VSV-G): 7 µg 
o Transfer plasmid (containing the transgene of interest within pHR' lentiviral 
backbone): 25 µg (if the size of promotor + transgene is ≤ 1,500 bp) or 32 µg (if 
the size of promotor + transgene is ≤ 3,000 bp) 
 To produce 3rd generation LVs, use a four-plasmid system at molar ratio 1:1:1:2 of 
packaging:rev:env:transfer plasmids: 
o Packaging plasmid (pMDLg/pRRE for IPLVs or pMDLg/pRREintD64V for 
IDLVs): 12.5 µg 
o REV plasmid (pRSV-REV): 6.25 µg 
o Envelope plasmid (pMD2.VSV-G): 7 µg 
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o Transfer plasmid (containing the transgene of interest within pRRL or pCCL 
lentiviral backbone): 25 µg (if the size of promotor + transgene is ≤ 1,500 bp) or 
32 µg (if the size of promotor + transgene is ≤ 3,000 bp) 
4. Make up the DNA mix to 112.5 µl with 1x TE buffer 
5. Top up with 1,012.5 µl tissue culture-grade water 
6. Add 125 µl 2.5 M CaCl2, vortex and leave for 5 min, RT 
7. Add 1,250 µl 2x HBS drop-wise while vortexing DNA/CaCl2 mix at full speed  
8. Immediately add the mix to HEK293T cells and gently mix with the culture medium  
9. Put cells back in incubator (maintained at 37oC, 5% CO2) 
10. Sixteen hours post-transfection, remove the medium and replace with 18 ml fresh 
medium per plate 
11. Twenty four hours after medium change, harvest cell supernatant, which contains 
viral vector particles (see Note 4)  
12. Centrifuge at 2,500 rpm (540 g) for 10 min, RT  
13. Filter supernatant through a 0.22 µm Nalgene filter (or a 0.45 µm Nalgene filter to 
minimize vector loss) 
14. Transfer filtered medium to high speed polyallomer centrifuge tubes (16 ml/tube) 
15. Ultracentrifuge at 23,400 rpm (50,000 g) for 2 h, 4oC 
16. Discard supernatant and keep tubes upside down on sterile paper towels for a few 
minutes to drain the remaining supernatant. Dry the last drops around the rim with 
paper towels 
17. Add 50 µl of DMEM without supplements (or 1x PBS if preferred) per tube 
18. Pipette up and down several times and transfer to 1.5 ml Eppendorf tube 
19. Centrifuge for 10 min at 4,000 rpm (864 g), 4oC to remove any aggregates. 
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20. Transfer the supernatant to new Eppendorf tubes 
21. Adjust vector stock to 10 mM MgCl2 with 1 M MgCl2 
22. Add 5 units/ml DNAse I and incubate for 30 min, 37o C 
23. Aliquot and store at -80o C 
24. Titrate vector stock to standardize amount of vector injected (see Note 5) 
 
3.2. Stereotactic injection of LVs 
1. Use Paxinos and Watson Rat Brain Atlas to determine injection site(s) (see Note 6)  
2. Set up stereotactic frame with nose bar at -3.3 mm (below the horizontal) 
3. Set up UltraMicroPump for automatic injection rate at 0.5 µl/min  
4. Autoclave all surgical tools prior to use  
5. Sterilize Hamilton syringe and needle with 70% ethanol, then wash with ddH2O and 
prime with viral vectors to prevent adsorption of the vector during dosing 
6. Place rat into an anaesthesia chamber and induce with 5% isoflurane in 100% O2 until 
the animal goes into deep anaesthesia (heart beats slowly and regularly) 
7. Shave the head fur and place rat on a heat pad, within the stereotactic frame, with 
anaesthesia maintained using approximately 2.5% isoflurane in 100% O2 
8. Place rat into stereotaxic frame and hang incisors on incisor bar. The rat is ready for 
surgery following loss of pedal withdrawal reflex and eye-blink reflex. Monitor state 
of anaesthesia throughout surgical procedure 
9. Cover two ear bars (of stereotactic frame) with Emla cream and set up the bars (see 
Note 7) 
10. Make a longitudinal incision in the scalp starting from the mid-line between the eyes 
and extending for ~1 mm towards the tail 
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11. Keep the scalp open with tweezers  
12. Gently wipe the skull with sterile paper towels 
13. Determine the position of bregma (see Note 8) and calculate the final values of AP 
and ML according to it 
14. Drill a burr-hole into the skull at the identified position and pierce dura using an 
sterile needle  
15. Read the DV value, calculate the final value needed and move the syringe down to 
the position corresponding to this value (see Note 6) 
16. Inject LVs using UltraMicroPump at a rate of 0.5 μl/min (see Note 6) 
17. During injection, rehydrate the rat with Aqupharm solution (10 ml/kg, s.c.)  
18. After injection, leave the needle in place for ~3 min prior to retracting it  
19. Suture the scalp, place rat in a clean, warm cage and wait until the animal regains 
consciousness  
20. Clean Hamilton needle and Vetsuture with 70% ethanol for the next injection 
21. After the last injection clean Hamilton syringe with 70% ethanol, then water before 
returning to its container 
 
3.3. 6-OHDA lesioning  
1. Thirty minutes prior to surgery, inject rat with a combined solution of pargyline (5 
mg/kg, i.p) and desipramine (25 mg/kg, i.p) (see Note 9)  
2. Carry out all steps listed in Section 3.2. However,  
- In step 5: prime the syringe with 6-OHDA solution instead of LV stock 
- In step 15: we inject 6-OHDA at the same locations as vector (see Note 10) 
- In step 20: discard remaining 6-OHDA 
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3. Timing of 6-OHDA lesioning (see Note 11) 
 
3.4. Post-mortem brain processing 
1. Sacrifice rats by CO2 exposure and decapitate 
2. Open the skull with medium scissors or forceps, remove the whole brain and transfer 
into 50 ml falcon tubes filled with ice-cold 4% PFA (1 brain/tube, see Note 12)  
3. Fix brains for 3-5 days at 4oC 
4. Rinse brains with ice-cold 1x PBS 
5. Slice brains on a vibrating microtome at 50 µm thickness 
6. Collect brain sections using a paint brush and keep in ice-cold 1x PBS during 
sectioning 
7. Wash in ice-cold 1x PBS (2 x 2 min) with gentle agitation  
8. Block in 1% BSA blocking buffer for 1 h, RT  
9. Incubate with primary antibody overnight, 4oC (see Note 13) 
10. Wash in 1x PBS (3 x 5 min) with gentle agitation 
11. Incubate with compatible secondary antibody for 1 h, RT (see Note 13). Protect 
samples from light after this step 
12. Wash in 1x PBS (3 x 5 min) with gentle agitation 
13. Incubate with DAPI (1 µg/ml) for 15 min, RT  
14. Wash in 1x PBS (3 x 5 min) with gentle agitation 
15. Use paint brush to flatten brain sections onto SuperFrost slides (~3 sections/slide)  
16. Mount with mounting solution (50-100 µl/slide) and cover with coverslips 
17. Air dry at RT and store at 4oC 
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4. Notes  
1. Mowiol may not be dissolved completely but the pellet must be colourless. After 
centrifugation, collect and aliquot the supernatant and store at -20oC until use. Do not 
disturb the pellet.  
2. As growth rate of 293T cells is quite variable, adjust cells seeded accordingly.  
3. Plasmid stocks and reagents are endotoxin-free and tissue culture grade. LV 
plasmids are self-inactivating and contain a central polypurine tract/central 
termination sequence and Woodchuck hepatitis virus post-transcriptional regulatory 
element. 
4. Replace culture medium again with 18 ml/plate of fresh medium for second harvest 
(after additional 24 h), if required. The first harvest usually provides the highest 
vector titres but the second harvest can have comparable yield. 
5. We favor titration of the late reverse transcript by qPCR (20) in transduced cells 
harvested 24 h post-transduction, normalizing with the amount of endogenous β-
actin gene, as described (9) and discussed (8). It is important to harvest transduced 
cells at 24 hours when titrating IDLVs (and matched IPLV stocks) by qPCR, to 
minimize loss of episomes due to cell proliferation-mediated dilution. 
6. We obtained successful LV transduction with widespread eGFP expression within 
the striatum following 2 injections at: (1) AP: +1.8 mm, ML: -2.5 mm relative to 
bregma and DV: -5.0 mm relative to dura; (2) AP: 0.0 mm, ML: -3.5 mm relative to 
bregma and DV: -5.0 mm relative to dura. Vectors were injected at 5 µl/site, 109 viral 
qPCR transducing units/ml (see Note 5). 
7. Two ear bars should be inserted at equivalent depth, usually around 7. If the bars are 
set at the right position, when you release incisors from the bar and use your index 
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finger to gently press the head down or lift it up, the head will move rigidly and not 
drift downwards. 
8. Be careful not to confuse bregma with lambda (just below bregma).  
9. Pargyline and desipramine are used to increase the bioavailability and specificity of 
6-OHDA for dopaminergic neurons.  
10. We used 6-OHDA at 2.5 µg/µl and injected 2 µl/site at two sites into the striatum and 
observed 50% death of dopaminergic neurons in the ipsilateral substantia nigra.  
11. 6-OHDA lesioning can be administered before or after LV injection depending on the 
purpose of the study. 
12. The volume of 4% PFA should be 10-20 times that of the brain for complete fixation. 
We used 20 ml/brain. 
13. Dilute antibodies in blocking buffer at concentrations according to manufacturers' 
recommendation or previous optimization. 
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